NeoGenomics is set to drop its Q2 earnings this Tuesday, having just smashed revenue targets last quarter with an 11.1% year-over-year jump to $186.7M — though they’ve missed targets before. Analysts expect a slight slowdown this time, forecasting 8.8% growth, down from last year’s 10.2%. While peers like Quest and Tenet are outperforming with strong beats and stock gains, NeoGenomics is lagging — down 2.5% in the last month despite a $13.89 stock price and a $16.78 target. Investors are watching closely to see if the cancer diagnostics leader can sustain momentum after a history of misses.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
